Pioglitazone
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Pioglitazone: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Pioglitazone is an oral insulin-sensitising diabetes medicine, and it is marketed in South Africa as tablets. The TxGNN model predicts it may be effective for opsismodysplasia, a rare skeletal dysplasia. Currently there are 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (general pharmacological knowledge; the SAHPRA records supplied do not state an indication) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Pioglitazone activates PPAR-gamma, which improves insulin sensitivity. Its efficacy in diabetes is established, but a mechanistic link to opsismodysplasia cannot be supported from the data provided.
Opsismodysplasia is a rare skeletal dysplasia, typically linked to loss of function of the INPPL1 gene. Pioglitazone’s insulin-sensitising action has no evident connection to that pathway. The high score of 99.59% is a graph-based association only. It is not backed by trials, literature or a demonstrated mechanism, so it should not be read as clinical support.
Eight other predictions were generated for this drug, and none has any trial or literature evidence. Four of them, all localised lipodystrophies, are flagged as “Research Question” because PPAR-gamma’s role in fat cell development offers a plausible hypothesis. These are drug-induced localised lipodystrophy, centrifugal lipodystrophy, pressure-induced localised lipoatrophy and idiopathic localised lipodystrophy. The stiff-person spectrum conditions, thiamine-responsive dysfunction syndrome and pancreatic agenesis were rated weaker and are on Hold.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| A40/21.2/0149 | Cipla-pioglitazone | Tablet | Not stated in the registration data supplied |
| 46/21.2/0257 | Pioglitazone Hydrochloride Tablets Macleods 15 Mg | Tablet | Not stated in the registration data supplied |
All registered products are oral tablets.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials and no literature, and it has no supported mechanistic link to the disease. The safety review cannot proceed because SAHPRA warnings and contraindications are missing.
To proceed, the following is needed:
- SAHPRA Professional Information (PI) warnings and contraindications, which are blocking for the safety screen
- Mechanism of action data, for example from DrugBank
- A targeted literature and trial search for opsismodysplasia, and for the localised lipodystrophy candidates, which have the most plausible mechanism
- Expert clinical review of whether the lipodystrophy candidates are a better repurposing direction than the top-ranked prediction
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.